MedTrace Logo

Acute Hip Fracture Study in Patients 65 Years or Greater

NCT02578095 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-12-29

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment.

Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.

Conditions

  • Hip Fractures

Interventions

DRUG

VK5211

Capsule

DRUG

Placebo

Capsule

Sponsors & Collaborators

  • Viking Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Marianne Mancini · Viking Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-30
Primary Completion
2017-11-15
Completion
2017-12-17

Countries

  • United States
  • Hungary
  • Romania
  • Serbia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02578095 on ClinicalTrials.gov